What this means
This study looks at whether selenium in the blood is linked to weak muscles and frailty in dialysis patients. It is a registration of a planned study, and it has not posted any results yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 18–70
- Where
- 1 site
The science
- Registered title
- Selenium, Sarcopenia, and Frailty in Hemodialysis
- Trial ID
- NCT07896876 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Frailty, Sarcopenia, Selenium
- What is tested
- FRAIL scale, sarc-f, time up go test, hand grip strength
- Sponsor
- Ankara City Hospital Bilkent
- Ages
- 18 Years to 70 Years
- Dates
- First posted Oct 27, 2026 · updated Oct 27, 2026
Registry summary
Chronic kidney disease (CKD) is a significant public health issue with an increasing prevalence worldwide. In patients undergoing hemodialysis (HD) in particular, various factors-such as chronic inflammation, oxidative stress, nutritional disorders, and micronutrient deficiencies-can negatively affect muscle health and physical function. Selenium, an essential trace element with potent antioxidant properties, has been shown to be present at low levels in these patients and may be associated with muscle strength. Sarcopenia and frailty are critical clinical conditions in HD patients that diminish quality of life and increase the risk of hospitalization and mortality. This study aims to evaluate the relationship between serum selenium levels, sarcopenia, and frailty in patients undergoing chronic hemodialysis, and to investigate whether selenium levels might serve as a potential biomarker for these clinical conditions.
Sites (1)
- Handan elif nur bayraktar, Samsun, Samsun, Turkey (Türkiye)